Search

Displaying results 3911 - 3920 of 10000 in total
  1. Target

    Serine/threonine-protein kinase SIK2

    go.drugbank.com/bio_entities/BE0009538
    TargetHumans

    Serine/threonine-protein kinase that plays a role in many biological processes such as fatty acid oxidation, autophagy, immune response or glucose metabolism (PubMed:23322770, PubMed:26983400). Phosphorylates 'Ser-794' of IRS1 in insulin...

    Synonyms: SIK-2
  2. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.

  3. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology

  4. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  5. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

  6. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.

  7. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Vayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503].

  8. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

    Synonyms: 4,5-dichloro-m-benzenedisulfonamide
  9. Drug

    Karaya gum

    go.drugbank.com/drugs/DB10535
    Approved

    Karaya gum allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  10. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.